Nivolumab and pembrolizumab, two antibodies that target PD-1 and block its interactions with PD-L1 and PD-L2, are approved for the treatment of advanced melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC), based on clinical studies that demonstrated improvements in overall survival [25,26]. This evidence concerns the gene PDCD1LG2 and renal cell carcinoma.